Global Human Immunodeficiency Virus (HIV) Diagnosis Market Report 2024

The HIV diagnosis market size has grown rapidly in recent years. It will grow from $3.79 billion in 2023 to $4.2 billion in 2024 at a compound annual growth rate (CAGR) of 11%. The growth observed in the historical period can be attributed to several key factors, including the expansion of voluntary counseling and testing programs, the development of HIV antibody tests enabling wider screening, the emergence of the HIV/AIDS epidemic prompting heightened awareness and response efforts, and the implementation of community-led and peer-led initiatives aimed at education and support.

The HIV diagnosis market size is expected to see rapid growth in the next few years. It will grow to $6.42 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to public health campaigns and awareness initiatives, focus on equity and inclusivity, routine testing in healthcare settings, community-led and peer-led approaches, and expansion of self-testing. Major trends in the forecast period include advancements in testing technologies, focus on targeted testing strategies, community-based testing and outreach, emphasis on equity and inclusivity, and policy and funding priorities.

The anticipated increase in blood donation is poised to drive the expansion of the HIV diagnosis market in the foreseeable future. Blood donation, characterized by the voluntary act of giving blood through phlebotomy, has seen a rise attributed to advancements in medical technology, heightened community engagement, and enhanced donor recruitment and retention strategies. This surge in blood donation results in a larger pool of samples available for HIV testing. Consequently, the heightened availability of blood samples facilitates more comprehensive screening for HIV antibodies or antigens, thereby improving the accuracy and reliability of HIV diagnosis. For example, NHS Blood and Transplant, a UK-based government agency, reported an increase in new blood donors from 119,016 in 2022-2023 to 119,371 in 2023-2024, underscoring the pivotal role of rising blood donation in propelling the growth of the HIV diagnosis market.

Major players in the HIV diagnosis market are actively developing chip-based real-time PCR test solutions tailored for HIV, aimed at enhancing accuracy, reducing turnaround time, and improving accessibility. Chip-based real-time PCR test solutions utilize microfluidic chips or small integrated circuits to conduct real-time polymerase chain reaction (PCR) tests for HIV detection. For instance, in August 2022, Molbio Diagnostics, an India-based molecular diagnostics manufacturer, unveiled the Truenat HIV-1 test, a chip-based real-time PCR test designed for the quantitative detection and diagnosis of human immunodeficiency virus type 1 (HIV-1) in whole blood and plasma. Leveraging Taqman chemistry, this test boasts high primer sensitivity and specificity, requiring minimal sample volume and featuring an intelligent chip with lot-specific data for result quantification, along with contamination- and evaporation-resistant design elements.

In May 2022, Roche, a Switzerland-based biopharmaceutical and diagnostic company, forged a partnership with the Global Fund, aiming to bolster diagnostic infrastructure in low- and middle-income countries. This collaboration seeks to facilitate improved diagnosis and treatment of HIV and tuberculosis within the framework of Roche's Global Access Program and the Global Fund's broader initiatives targeting HIV, tuberculosis, and malaria globally. The Global Fund, an international financing and partnership organization headquartered in Switzerland, focuses on providing grants to strengthen health systems addressing HIV/AIDS.

Major companies operating in the human immunodeficiency virus (HIV) diagnosis market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Becton Dickinson and Company, Hologic Inc., bioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Alere Inc., Cepheid Inc., OraSure Technologies Inc., Advanced Instruments Inc., BBI Solutions, Chembio Diagnostic Systems Inc., BioLytical Laboratories Inc., Avioq Inc., Advanced Biochemicals Ltd., Advanced Molecular Diagnostics, Atila BioSystems Inc., BioAssay Works LLC, Chemtron Biotech Inc.

North America was the largest region in the HIV diagnosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus (HIV) diagnosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human immunodeficiency virus (HIV) diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human immunodeficiency virus (HIV) diagnosis encompasses the process of determining whether an individual has contracted the human immunodeficiency virus, which leads to acquired immunodeficiency syndrome (AIDS). This diagnostic procedure involves testing for the presence of HIV antibodies, antigens, or viral genetic material in bodily fluids such as blood, saliva, or other relevant specimens.

The primary products utilized in HIV diagnosis include consumables, instruments, and software and services. Consumables refer to materials or supplies that are used up during diagnostic procedures, and they can be deployed in various formats including self-tests and lab-based assays. These products find application across diverse end users such as diagnostic laboratories, hospitals, and research institutions.

The HIV diagnosis market research report is one of a series of new reports that provides HIV diagnosis market statistics, including HIV diagnosis industry global market size, regional shares, competitors with a HIV diagnosis market share, detailed HIV diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the HIV diagnosis industry. This HIV diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human immunodeficiency virus (HIV) diagnosis market consists of revenues earned by entities by providing services such as HIV testing, pre-test counseling, post-test counseling, laboratory-based testing, point-of-care testing, partner notification services, and linkage to care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The human immunodeficiency virus (HIV) diagnosis market also includes sales of diagnostic kits, testing equipment such as enzyme-linked immunosorbent assay (ELISA) readers and polymerase chain reaction (PCR) machines, point-of-care testing devices, laboratory equipment such as centrifuges and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.